Whether one uses an exponential model or a linear model to describe the concentration data would matter only if these equations were to be used to predict concentrations of trace gases expected in the future. Such an extrapolation, however, is neither recommended nor was it even implied in (1) . The rates of increase reported are designed to be used to test or establish the parameters of a global mass balance model and then to compute concentrations expected in the future based on probable scenarios of future global emissions. In general, such projections based on the mass balance of CC13F (F-I 1), CCl2F2 (F-12) , and CH3CC13 would not agree with either a simple linear or an exponential extrapolation of currently observed increases in these gases. For our data, the exponential model of increase is preferable as we will show here.
Since 1974 the global emissions of CH3CC13 have been rising at about 7 percent per year, and the emissions of F-11 and F-12 may have been falling at 3 to 4 percent per year, although some believe that the annual emissions of F-12 are still rising (2) . For more than 20 years before 1974, the global emissions of F-11, F-12, and CH3CC13 had been rising exponentially at between 12 and 16 percent per year (3) . Because of these yearto-year increases, decreases, or fluctuations in the global emissions and the finite lifetimes of these trace gases, matching the observed increase in atmospheric concentrations to a linear function [c = k1t + k2, where c is the atmospheric concentration in parts per trillion by volume (pptv), t is the elapsed time, and k, and k2 are constants] is only an approximation, which at least over short time periods is no better than matching neurologic impairment was not quantified, only 34 of the 59 gerbils with signs of stroke were experimentally accounted for, and a statistical evaluation of the results was not provided.
Because raters using neurologic signs to evaluate function tend to be subjective, it is essential for them to be naive as to treatment group and for the experimental and control animals to be evaluated simultaneously to eliminate temporal variabilities. We found that simple handling of neurologically impaired gerbils resulted in a decrease in the apparent intensity of signs within 3 to 5 minutes (2). This effect, which lasted 15 to 30 minutes (2) , is therefore similar to what Hosobuchi and colleagues attribute to naloxone treatment in ten gerbils (1) . For this reason, our treatment groups were run concurrently and neurologic function was evaluated by a rater who was unaware of the treatment categories (2) .
The pharmacological effects of opiates closely resemble the neurologic deficits induced in gerbils by carotid occlusion (effects on locomotion, decreased responsiveness or "coma," loss of righting reflexes). Indeed, we confirmed that morphine increased the severity of "neurologic" signs as well as mortality. However, demonstration of the stereospecificity of pharmacological responses to injected alkaloid opiates does not prove that endogenous opiates acting at opiate receptors are involved in the neurologic deficits produced by permanent unilateral carotid occlusion.
Since we found that naloxone and thyrotropin releasing hormone (TRH) prevent neurologic deficits in cats subjected to experimental spinal cord trauma (3), we tested the effects of these drugs on the ischemic neurologic deficits produced by temporary bilateral carotid occlusion in gerbils. Permanent carotid occlusion would have prevented vascular access of injected drugs and blocked any improvement in blood flow to the ischemic areas in question. Unlike temporary carotid occlusion, the permanent unilateral occlusion model appears to be more relevant to problems associated with infarction and cerebral edema (4) .
Temporary bilateral occlusion appears to result in hypotension as well as neurologic deficits (2) . The hypotension that followed 15 minutes of bilateral occlusion was reversed by naloxone (5 mg/kg) as well as by TRH (2 mg/kg) injected intravenously.
We evaluated functional neurologic recovery in gerbils that had been subjected to 30 minutes of bilateral carotid occlusion (5). Except that TRH increased the 5 NOVEMBER 1982 respiration rates of these animals, neither naloxone nor TRH had significant effects on time to wake up, time to death, neurologic scores (ptosis, movement, retracted paws, circling, righting reflexes, seizures, and opisthotonus), hot-plate latencies, or roto-rod performance. With ten gerbils per group (5), 60 percent of the gerbils were dead within 8 hours (80 percent dead within 3 days) regardless of drug treatment. Thus, despite improved cardiovascular and respiratory function after naloxone or TRH administration, the complete absence of improved neurologic function or survival (2) indicated that these drugs were without therapeutic effects in this model of cerebral ischemia (6).
Hosobuchi et al. (7) reported successful reversal of hemiparesis by naloxone in gerbils subjected to permanent unilateral carotid occlusion. Since our results were obtained with temporary bilateral occlusion, we investigated the effects of saline, naloxone, and TRH (as well as morphine) in gerbils subjected to permanent unilateral occlusion. In lightly anesthetized gerbils, the right common carotid was doubly ligated, and the animals were randomly divided into groups that received saline (N = 27) or naloxone (N = 28) (5). Naloxone did not improve the neurologic scores (-36 percent had positive signs) or the mortality (-25 percent in both groups), respiratory rates, or any other index of neurologic function (2) . We also attempted to duplicate the methodology of Hosobuchi et al., administering 1 mg of naloxone per kilogram 5 to 6 hours after occlusion, but again we obtained negative results. However, both morphine (10 mg/kg plus one 75-mg pellet) and TRH (as before) exacerbated the neurologic deficits and increased the mortality; 70 percent of the gerbils treated with these drugs showed severe neurologic impairment and died within 7 days (2).
Although these authors correctly noted our finding (3) that naloxone prevents neurologic deficits (associated with injury-induced neuronal ischemia) following spinal trauma, they were incorrect in reporting that we injected naloxone intracerebrally ( The clinical findings by Hosobuchi et al. document a lack of effect of naloxone in reversing hemiplegia in one patient with radiographically documented areas of cerebral infarction (1). However, naloxone was reported to temporarily reverse the hemiplegia in two patients whose neurologic impairment was not due to hypoperfusion resulting from a permanent infarction. Since naloxone did not work in a patient with documented cerebral infarction, the permanent carotid infarction model in the gerbil appears to have been inappropriate for evaluation of this hypothesis. On the basis of their data with humans (1), one would not expect naloxone to improve neurologic deficits induced by permanent carotid occlusion in the gerbil.
Thus Hosobuchi et al. do not provide convincing evidence that endorphins are involved in the neurologic deficits caused by permanent unilateral occlusion in gerbils. We found that naloxone had no therapeutic effect on cerebral ischemia in the gerbil. However, by means of an air embolism model of cerebral ischemia in dogs, naloxone was recently shown to improve local cerebral blood flow and somatosensory responses (9). Since cerebral ischemia can have many causes that may be of central or peripheral origin, and since different species may vary considerably in their physiological response to trauma [for example, "no reflow" responses (10)], it is evident that the fundamental hypothesis that endorphins contribute to the neurologic deficits resulting from cerebral ischemia requires further animal evaluation before human trials are considered.
mg naloxone pellet (6), or (iii) TRH (8 mg/kg; Beckman) plus 2 mg of TRH in gelatin. Intraperitoneal drugs (0.10 to 0.12 ml, depending on gerbil size) were injected upon release of the clips, and repository doses were administered (in subcutaneous pellet or gel form) immediately thereafter. Naloxone pellets containing 10 mg of naloxone (free base) were from the same source as those used by Hosobuchi et al. We thank H. H. Loh for providing these pellets. The pellets were placed subcutaneously over the hip; the TRH-gel (2 mg of TRH in 0.10 ml) was injected subcutaneously in the same area. The role of endogenous opioid ligands in the pathophysiology of cerebral ischemia is still poorly defined, and we enthusiastically support-further experiments before naloxone is used widely for the treatment of cerebral ischemia in humans. We cannot agree, however, with the conclusions of Holaday and DWAmato (1) concerning our experiments in gerbils.
Holaday and D'Amato (1) report that, using two different models of stroke in the gerbil, they could not reproduce our finding (2) that naloxone reverses ischemia-induced neurologic deficits in this species. The model they used for most of their experiments-bilateral carotid occlusion to produce a 30-minute "noflow" state-is a well-accepted model for global cerebral ischemia. This model bears no relation lb the model of focal cerebral ischemia from unilateral carotid occlusion that we used in our expetiments. Therefore (2) , these gerbils developed focal deficits after the administration of morphine; the effect was both stereospecific and receptor-specific.
We have recently reported (4, 5) the naloxone reversal of ischemic neurologic deficits in cats and baboons that underwent middle cerebral artery occlusion.
In neither animal model did we note changes in blood pressure, heart rate, arterial blood gases, cardiac output, or cardiac filling pressures after naloxone administration despite reversal of neurologic deficit.
Interlaboratory discrepancies in results of experiments with gerbil models are characteristic of research in stroke.
The age and sex of gerbils play a significant role in the size and extent of induced infarction and in the response to therapeutic intervention (6 
